Etigilimab Biosimilar – Anti-TIGIT, VSTM3 mAb – Research Grade

Etigilimab Biosimilar – Anti-TIGIT, VSTM3 mAb – Research Grade: A Promising Antibody Targeting TIGIT for

Cancer Immunotherapy Introduction

Etigilimab Biosimilar, also known as Anti-TIGIT, VSTM3 mAb, is a promising antibody that has shown potential in cancer immunotherapy. This biosimilar is designed to target TIGIT, a protein that plays a crucial role in regulating immune response and tumor progression. In this article, we will discuss the structure, activity, and potential applications of Etigilimab Biosimilar in detail.

Structure of Etigilimab Biosimilar

Etigilimab Biosimilar is a monoclonal antibody (mAb) that is produced by recombinant DNA technology. It is a humanized IgG1 antibody that specifically binds to TIGIT, a protein that belongs to the immunoglobulin superfamily. The antibody has a molecular weight of approximately 150 kDa and consists of two heavy chains and two light chains. The heavy chains are composed of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains consist of two constant domains (CL) and one variable domain (VL). The variable domains are responsible for binding to TIGIT and initiating an immune response.

Activity of Etigilimab Biosimilar

TIGIT is a co-inhibitory receptor that is expressed on the surface of various immune cells, including T cells, natural killer (NK) cells, and regulatory T cells (Tregs). It interacts with its ligands, CD155 and CD112, to suppress immune response and promote immune tolerance. This mechanism is exploited by cancer cells to evade detection and destruction by the immune system. Etigilimab Biosimilar works by blocking the interaction between TIGIT and its ligands, thereby releasing the brakes on the immune system and allowing it to mount an effective anti-tumor response. This antibody also has the ability to enhance the activity of other immune cells, such as NK cells and T cells, further strengthening the immune response against cancer cells.

Applications of Etigilimab Biosimilar

Etigilimab Biosimilar is being investigated as a potential treatment for various types of cancer, including melanoma, lung cancer, and breast cancer. It has shown promising results in preclinical studies, where it has been found to inhibit tumor growth and improve survival rates. In addition, this antibody has also been studied in combination with other cancer therapies, such as immune checkpoint inhibitors and chemotherapy, and has shown synergistic effects. Etigilimab Biosimilar is currently in clinical trials for the treatment of advanced solid tumors and is expected to enter the market as a research grade antibody in the near future.

Conclusion

In summary, Etigilimab Biosimilar – Anti-TIGIT, VSTM3 mAb – Research Grade is a novel antibody that targets TIGIT, a protein involved in immune regulation and tumor progression. Its unique mechanism of action makes it a promising candidate for cancer immunotherapy. The structure of this antibody, consisting of two heavy chains and two light chains, allows it to specifically bind to TIGIT and block its interaction with ligands. This leads to the activation of the immune system and the suppression of tumor growth. Etigilimab Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials. With further research and development, this antibody has the potential to become a valuable tool in the fight against cancer.